Hippocampal proton MR spectroscopy in early alzheimer's disease and mild cognitive impairment

Brain Topography

Volumn 24, Issue 3-4, 2011, Pages 316-322

  Foy, Catherine M L ^a   Daly, Eileen M ^a   Glover, Amanda ^a,b   O'Gorman, Ruth ^a   Simmons, Andrew ^a,b   Murphy, Declan G M ^a,b   Lovestone, Simon ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Algorithm; Alzheimer's disease; Diagnosis; MRS; Post mortem

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; INOSITOL; N ACETYLASPARTIC ACID;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASPARTIC ACID; CASE-CONTROL STUDIES; CHOLINE; CREATINE; FEMALE; HIPPOCAMPUS; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MILD COGNITIVE IMPAIRMENT; PHOSPHOCREATINE; PROTONS;

EID: 80755163486     PISSN: 08960267     EISSN: 15736792     Source Type: Journal    
DOI: 10.1007/s10548-011-0170-5     Document Type: Article

References (36)

1. Ackl N, Ising M, Screiber YA et al (2005) Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 384:23-28
2. Adalsteinsson E, Sullivan EV, Kleinhans N et al (2000) Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 355:1696-1697 (Pubitemid 30248487)
3. Bruscoli M, Lovestone S (2004) Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 16: 129-140 (Pubitemid 38963102)
4. Catani M, Cherubini A, Howard R, Tarducci R, Pelliccioli GP, Piccirilli M, Gobbi G, Senin U, Mecocci P (2001) 1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 12(11):2315-2317 (Pubitemid 32682179)
5. Chantal S, Braun CMJ, Bouchard RW et al (2004) Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 1003:26-35 (Pubitemid 38317081)
6. Chantal S, Labelle M, Bouchard RW, Braun CM, Boulanger Y (2002) Correlation of regional proton magnetic resonance spectroscopic metabolic changes with cognitive deficits in mild Alzheimer disease. Arch Neurol 59:955-962 (Pubitemid 34640755)
7. Christiansen P, Toft P, Larsson HBW et al (1993) The concentration of N-acetyl asparate, creatine ? phosphocreatine and choline in different parts of the brain in adulthood and senium. Magn Reson Imaging 11:799-806
8. Dixon RM, Bradley KM, Budge MM et al (2002) Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 125:2332-2341
9. Ernst T, Chang L, Melchor R et al (2004) Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 203:829-836
10. Falini A, Bozzali M, Magnani G et al (2005) A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 26:1159-1163 (Pubitemid 40806494)
11. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
12. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN (1996) Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 119(Pt 6):2001-2007
13. Huang W, Alexander GE, Chang L et al (2001) Brain metabolite concentration and dementia severity in Alzheimer's disease: a 1H MRS study. Neurology 57:626-632 (Pubitemid 32782989)
14. Jack CR Jr, Petersen RC, O'Brien PC, Tangalos EG (1992) MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology 42:183-188
15. Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E (1997) Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49:786-794 (Pubitemid 27428023)
16. Juottonen K, Laakso MP, Partanen K, Soininen H (1999) Comparative MR analysis of the entorhinal cortex and hippocampus in diagnosing Alzheimer disease. AJNR Am J Neuroradiol 20: 139-144 (Pubitemid 30417684)
17. Kantarci K (2007) 1H magnetic resonance spectroscopy in dementia. Br J Radiol 80(Spec No 2):146-152
18. Kantarci K, Jack CRJ, Xu YCM et al (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology 55:210-217 (Pubitemid 30604620)
19. Kantarci K, Xu Y, Shiung MM et al (2002) Comparative diagnostic utility of differentMRmodalities in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 14:198-207 (Pubitemid 36151487)
20. Kantarci K, Weigand SD, Petersen RC et al (2006) Longitudinal (1)H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 28:1330-1339
21. McKhann G, Drachman D, FolsteinMet al (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34:939-944 (Pubitemid 14076461)
22. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39(9):1159-1165 (Pubitemid 19239715)
23. Parnetti L, Tarducci R, Presciutti O, Lowenthal DT, Pippi M, Palumbo B, Gobbi G, Pelliccioli GP, Senin U (1997) Proton magnetic resonance spectroscopy can differentiate Alzheimer's disease from normal aging. Mech Ageing Dev 97:9-14 (Pubitemid 27279860)
24. Petersen RC, Stevens JC, Ganguli M et al (2001) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology. Neurology 56:1133-1142
25. Provencher SW (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30:672-679 (Pubitemid 23360802)
26. Robertson DM, van Amelsvoort TM, Daly EB, Simmons A, Whitehead MM, Morris R, Murphy KC, Murphy DGM (2001) Effects of estrogen replacement therapy on human brain aging: an in vivo 1H MRS study. Neurology 57:2114-2117 (Pubitemid 33126884)
27. Rose SE, de Zubicaray GI, Wang D, Galloway GJ, Chalk JB, Eagle SC, Semple J, Doddrell DM (1999) A 1H MRS study of probable Alzheimer's disease and normal aging: implications for longitudinal monitoring of dementia progression. Magn Reson Imaging 17:291-299 (Pubitemid 29053189)
28. Schuff N, Amend D, Ezekiel F et al (1997) Changes of hippocampal Nacetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49:1513-1521 (Pubitemid 28015109)
29. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Alzheimer's Disease Neuroimaging Initiative (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4):403-413
30. Simmons A, Arridge SR, Barker G et al (1996) Simulation of MRI cluster plots and application to neurological segmentation. Magn Reson Imaging 14:73-92 (Pubitemid 26070801)
31. Simmons A, Smail M, Moore E, Williams SCR (1998) Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magn Reson Imaging 16(3):319-330 (Pubitemid 28264528)
32. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund L-O, Kinsey A, Guentert A, Proitsi P, Powell J, Causevic M, Killick R, Lynham S, Broadstock M, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney S, Ward M, Kloszewska I, Mecozzi P, Soininen H, Tsolaki M, Vellas B, Williams J, Murphy D, Parkins I, Resnick S, Ferucci L, Wong D, Zhou Y, Muehlboeck S, Evans A, Francis P, Spenger C, Lovestone L for the AddNeuroMed consortium (2010) Clusterin, an amyloid chaperone protein in plasma, is associated with severity, pathology and progression in Alzheimer's disease. Arch Gen Psych 67(7):739-748
33. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and, National Institute on Aging Working Group (1998) Consensus report of the working group on: "molecular and biochemical markers of Alzheimer's disease". Neurobiol Aging 19:109-116
34. Valenzuela MJ, Sachdev P (2001) Magnetic resonance spectroscopy in AD. Neurology 56:592-598 (Pubitemid 32209990)
35. Xu Y, Jack CR Jr, O'Brien PC, Kokmen E, Smith GE, Ivnik RJ, Boeve BF, Tangalos RG, Petersen RC (2000) Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology 54:1760-1767 (Pubitemid 30428402)
36. Yesavage JA (1988) Geriatric depression scale. Psychopharmacol Bull 24:709-711